Relatlimab and nivolumab in the treatment of melanoma
Abstract
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
Journal details
Journal Cell
Volume 185
Issue number 26
Pages 4866-4869
Available online
Publication date
Full text links
Publisher website (DOI) 10.1016/j.cell.2022.12.003
Europe PubMed Central 36563660
Pubmed 36563660
Keywords
Related topics
Type of publication